Prospective Evaluation of Efficacy and Safety of an Intense Pulsed Light Device to Treat Dry Eye Disease"

Inclusion Criteria:

• Patient is able to read, understand and sign an information consent and image rightforms

• aged over 22 years old

• Fitzpatrick skin type I-IV

• Patient is able and willing to comply with the treatment/FU schedule andrequirements

• Meibomian Gland Score : Meibum Quality according to Tear Film and Occular SurfaceSociety recommendation: ≥ 16 for 1 eye and 8 central glands in the lower eyelid

• At least 5 non-atrophied meibomian glands in the lower eyelid

• Tear break-up time (TBUT) ≤ 10 seconds

• Symptoms self-assessed using the Occular Surface Disease Index questionnaire ≥ 23

Exclusion Criteria:

• Fitzpatrick skin type V or VI

• Contact lens wear within the month prior to screening

• Unwilling to discontinue use of contact lenses for the duration of the study

• Ocular surgery or eyelid surgery within 6 months prior to screening

• Neuro-paralysis in the planned treatment area within 6 months prior to screening

• Other uncontrolled eye disorders affecting the ocular surface, for example activeallergies

• Current use of punctal plugs

• Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatmentarea Uncontrolled infections or uncontrolled immunosuppressive diseases

• Patients with ocular infections, within 6 months prior to screening

• Prior history of cold sores or rashes in the perioral area or in the plannedtreatment area that could be stimulated by light at a wavelength of 610 nm to 1200nm, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus, and porphyria

• Within 3 months prior to screening, use of photosensitive medication and/or herbsthat may cause sensitivity to 610-1200 nm light exposure, including: Isotretinoin,Tetracycline, Doxycycline, and St. John's Wort

• Over exposure to sun, within 4 weeks prior to screening

• Using of topical drops, only artificial tears and glaucoma treatments are authorized

• Radiation therapy to the head or neck, within 12 months prior to screening

• Planned radiation therapy, within 8 weeks after the last treatment session

• Treatment with chemotherapeutic agent, within 8 weeks prior to screening

• Planned chemotherapy, within 8 weeks after the last treatment session

• New topical treatments within the area to be treated (face), or oral therapies,within 3 months prior to screening, analgesics for pain management, oral omega 3fatty acid supplements are authorized

• Change in dosage of any systemic medication, within 3 months prior to screening

• Anticipated relocation or extensive travel outside of the local study areapreventing compliance with follow-up over the study period

• Legally blind in either eye

• History of migraines, seizures or epilepsy

• Facial Itense Pulsed Light treatment, within 12 months prior to screening

• Any thermal treatment of the eyelids, including Lipiflow, within 6 months prior toscreening

• Expression of the meibomian glands, within 6 months prior to screening

• In either eye, moderate to severe (Grade 3-4 on the EFRON scale) inflammation of theconjunctiva, including: allergic, vernal or giant papillary conjunctivitis

• In either eye, severe (Grade 4 on the EFRON scale) inflammation of the eyelid,including: blepharochalasis, staphylococcal blepharitis or seborrheic blepharitis

• Ocular surface abnormality that may compromise corneal integrity in either eye (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect,Grade 3 corneal fluorescein staining, or map dot fingerprint dystrophy andpterigyum)

• Eyelid abnormalities that affect lid function in either eye, including: entropion,ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, and severeptosis

• Any systemic condition that may cause dry eye disease, including: Stevens-Johnsonsyndrome, vitamin A deficiency, rheumatoid arthritis, Wegener's granulomatosis,sarcoidosis, leukemia, Riley-Day syndrome, systemic lupus erythematosus, andSjögren's syndrome

• Unwilling or unable to abstain from the use of medications known to cause dryness (e.g., isotretinoin, antihistamines) throughout the study duration. Patients mustdiscontinue these medications for at least 1 month prior to the baseline visit.

• Any condition revealed whereby the investigator deems the Patient inappropriate forthis study